PD-L1 therapy
PD-L1 therapy is an innovative treatment modality in the field of cancer immunotherapy. It works by blocking the interaction between the programmed cell death protein (PD-1) and its ligand (PD-L1), essentially reinvigorating the body’s immune system to attack cancer cells. Notable for its application in treating various cancers, such as lung cancer, kidney cancer, and melanoma, PD-L1 therapy has revolutionized the approach towards cancer treatment, proving effective for some patients who had limited options. However, the therapy may cause immune-related side effects, requiring careful patient monitoring.
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian